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to view.Percutaneous Left Atrial Appendage Closure: Procedural Techniques and Outcomes 1205
Jacqueline Saw, Mathieu LempereurPercutaneous left atrial appendage closure for stroke prevention in patients with atrial ﬁbrillation has
signiﬁcantly advanced in the past 2 decades. Numerous devices are under clinical investigation and a
few have received the Conformité Européene (CE) mark. The leading endocardial devices, Watchman
and Amplatzer Cardiac Plug, have good safety and emerging efﬁcacy data. Currently, left atrial
appendage closures are typically performed for patients at high stroke risk who are poor
candidates for long-term anticoagulation. The imminent approval of Watchman for warfarin-
eligible patients will radically change the landscape of this therapy. This paper reviews in depth
the procedural techniques, safety, and outcomes of the current leading devices.CLINICAL RESEARCH
STRUCTURAL Risk of Cerebrovascular Events in Patients With Patent Foramen Ovale and
Intracardiac Devices1221Kanhaiya L. Poddar, Vijaiganesh Nagarajan, Amar Krishnaswamy, Navkaranbir S. Bajaj,
Meera Kumari, Hazem Bdair, Dhruv Modi, Shikhar Agarwal, Sachin S. Goel,
Akhil Parashar, E. Murat Tuzcu, Samir R. KapadiaThe authors sought to investigate whether patients with patent foramen ovale (PFO) have an increased
risk of stroke due to permanent pacemaker (PPM)/implantable cardioverter-deﬁbrillator (ICD)
implantation. There were 2,690 patients in the no device group and 231 patients in the device
group. The incidence of ischemic stroke was assessed in each group after propensity score matching
(case:control ratio of 1:1 yielding 231 pairs). Six patients (2.6%) in the no device group and 6 (2.6%)
in the device group had a stroke during the follow-up period. In patients with PFO, without a history
of stroke, device implantation might not be considered a risk factor for future stroke occurrence.CONTINUED ON PAGE A-21
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NOVEMBER 2014 VOLUME 7, NUMBER 11Periprocedural Complications and Long-Term Outcome After Alcohol Septal
Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy:
A Single-Center Experience1227Robbert C. Steggerda, Kevin Damman, Jippe C. Balt, Max Liebregts, Jurriën M. ten Berg,
Maarten P. van den BergComplications and outcome after alcohol septal ablation (ASA) and myectomy for symptomatic
hypertrophic obstructive cardiomyopathy were retrospectively analyzed. Long-term mortality
during a maximal follow-up of 11 years was comparable. After multivariate analysis, the only
predictor for all-cause mortality was age (per 5 years) (hazard ratio: 1.34 [95% conﬁdence
interval: 1.08 to 1.65], p ¼ 0.007), but not type of procedure (ASA vs. myectomy). Also long-
term symptomatic relief and clinical outcome were comparable. After ASA, periprocedural
complications were, however, less common and duration of hospital stay was shorter, although
gradients at late follow-up were higher compared with myectomy.n EDITORIAL COMMENT
Myectomy Versus Alcohol Septal Ablation: Experience Remains Key 1235
Jeffrey B. Geske, Bernard J. Gersh
Predictors of Carotid Occlusion Intolerance During Proximal Protected
Carotid Artery Stenting1237Giuseppe Giugliano, Eugenio Stabile, Giancarlo Biamino, Giampaolo Petroni,
Anna Sannino, Linda Brevetti, Armando Pucciarelli, Grigore Popusoi, Tullio Tesorio,
Angelo Cioppa, Linda Cota, Luigi Salemme, Antonio Sorropago, Angelo Ausania,
Giovanni Della Pietra, Arturo Fontanelli, Bruno Trimarco, Giovanni Esposito,
Paolo RubinoThe use of endovascular occlusion during carotid artery stenting (CAS) has been demonstrated to be
particularly safe and effective. However, endovascular occlusion can expose the ipsilateral
hemisphere to hypoperfusion and produce transient neurological symptoms (occlusion intolerance
[OI]). The aim of this study was to identify predictors of OI developing during proximal protected
CAS. OI may occur in as many as one-third of the patients undergoing proximal protected CAS.
This event was more common in those patients with an OP #40 mm Hg. Patients presenting with
concomitant occlusion of the contralateral internal carotid artery more frequently have an OP #40
mm Hg.CONTINUED ON PAGE A-22
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NOVEMBER 2014 VOLUME 7, NUMBER 11Outcomes After Transfemoral Transcatheter Aortic Valve Replacement: A Comparison
of the Randomized PARTNER (Placement of AoRTic TraNscathetER Valves) Trial With
the NRCA (Nonrandomized Continued Access) Registry1245William F. Fearon, Susheel Kodali, Darshan Doshi, Michael P. Fischbein, Alan C. Yeung,
E. Murat Tuzcu, Charanjit S. Rihal, Vasilis Babaliaros, Alan Zajarias, Howard C. Herrmann,
David L. Brown, Michael Mack, Paul S. Teirstein, Brian K. Whisenant, Raj Makkar,
Samir Kapadia, Martin B. Leon, on behalf of the PARTNER Trial InvestigatorsThe objective of this study is to determine whether outcomes for transfemoral transcatheter aortic
valve replacement differ between the randomized controlled trial and the subsequent NRCA
(Nonrandomized Continued Access) registry of the PARTNER (Placement of AoRTic TraNscathetER
Valve) trial. The authors found that patients included in the NRCA had signiﬁcantly lower rates of
vascular complications and major bleeding at 30 days. One-year mortality rates were signiﬁcantly
lower in the NRCA, and cerebrovascular events tended to be lower. The large NRCA registry
demonstrates further improvement in procedural and longer-term outcomes after transfemoral
transcatheter aortic valve replacement when compared with the favorable results from the
PARTNER randomized controlled trial.n EDITORIAL COMMENT
Outcomes After Transfemoral Transcatheter Aortic Valve Replacement 1252
Martyn Thomas
One-Year Follow-Up of the Melody Transcatheter Pulmonary Valve
Multicenter Post-Approval Study1254Aimee K. Armstrong, David T. Balzer, Allison K. Cabalka, Robert G. Gray,
Alexander J. Javois, John W. Moore, Jonathan J. Rome, Daniel R. Turner,
Thomas M. Zellers, Jacqueline KreutzerThe authors sought to conﬁrm that the effectiveness of the Melody transcatheter pulmonary valve
(Medtronic, Inc., Minneapolis, Minnesota) to treat dysfunctional right ventricular outﬂow tract
conduits achieved by real-world providers is equivalent to that found in the initial U.S. trial. The
procedural success rate for the 100 patients undergoing implantation was 98.0%. Acceptable
hemodynamic function at 6 months was achieved in 96.7%, with similar results at 1 year. No
patient required catheter reintervention, and 2 underwent reoperation during the ﬁrst year. This
ﬁrst prospective, real-world experience in the United States demonstrates continued high
procedural success, excellent short-term function, and low reintervention and reoperation rates.n EDITORIAL COMMENT
Transcatheter Pulmonary Valve Implants: The Unchained Melody 1263
Carlos E. Ruiz, Chad KligerCONTINUED ON PAGE A-23
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NOVEMBER 2014 VOLUME 7, NUMBER 11CORONARY Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents:
The DEFINITION Study (Deﬁnitions and impact of complEx biFurcation lesIons on clinical
outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts)1266Shao-Liang Chen, Imad Sheiban, Bo Xu, Nigel Jepson, Chitprapai Paiboon, Jun-Jie Zhang,
Fei Ye, Teugh Sansoto, Tak W. Kwan, Michael Lee, Ya-Ling Han, Shu-Zheng Lv,
Shang-YuWen, Qi Zhang, Hai-ChangWang, Tie-Ming Jiang, YanWang, Liang-Long Chen,
Nai-Liang Tian, Feng Cao, Chun-Guang Qiu, Yao-Jun Zhang, Martin B. LeonCriteria differentiating simple from complex bifurcation lesions were established using data from
1,500 patients with different patterns of bifurcation lesions, and the criteria were tested in
another 3,660 true bifurcation lesions. Two-stent techniques exhibited 1-year major adverse
cardiac event rates equivalent to the provisional stenting approach, but patients with complex
lesions likely beneﬁted from 2-stent techniques.
Hybrid Revascularization for Multivessel Coronary Artery Disease 1277
Mariusz Ga˛sior, Michael Oscar Zembala, Mateusz Tajstra, Krzysztof Filipiak,
Marek Gierlotka, Tomasz Hrapkowicz, Michał Hawranek, Lech Polonski,
Marian Zembala, on behalf of the POL-MIDES (HYBRID) Study InvestigatorsThe purpose of this study was to assess the feasibility of hybrid coronary revascularization (HCR) in
patients with multivessel coronary artery disease (MVCAD) referred for standard coronary artery
bypass grafting (CABG). The limitations of standard CABG and the unsatisfactory long-term
patency of saphenous grafts are commonly known. The primary endpoint was the evaluation of
the feasibility of HCR. Most of the pre-procedural characteristics were similar in the 2 groups. Of
the patients in the hybrid group, 93.9% had complete HCR, and 6.1% patients were converted to
standard CABG. Hybrid coronary revascularization is feasible in selected patients with MVCAD.n EDITORIAL COMMENT
Hybrid Coronary Revascularization: A New Treatment Paradigm for
Selected Patients With Multivessel Coronary Artery Disease1284John D. Puskas, Amit Pawale, Samin K. SharmaCONTINUED ON PAGE A-24
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NOVEMBER 2014 VOLUME 7, NUMBER 11Intravascular Ultrasound Guidance to Minimize the Use of Iodine Contrast in
Percutaneous Coronary Intervention: The MOZART (Minimizing cOntrast utiliZation With
IVUS Guidance in coRonary angioplasTy) Randomized Controlled Trial1287José Mariani Jr, Cristiano Guedes, Paulo Soares, Silvio Zalc, Carlos M. Campos,
Augusto C. Lopes, André G. Spadaro, Marco A. Perin, Antonio Esteves Filho,
Celso K. Takimura, Expedito Ribeiro, Roberto Kalil-Filho, Elazer R. Edelman,
Patrick W. Serruys, Pedro A. LemosPatients at high risk of contrast-induced acute kidney injury or volume overload were randomized to
angiography-guided percutaneous coronary intervention (PCI) (n ¼ 42) or intravascular ultrasound
(IVUS)-guided PCI (n ¼ 41). The median total volume of contrast (primary endpoint) was 64.5 ml
(interquartile range [IQR]: 42.8 to 97.0 ml) in the angiography-guided group versus 20.0 ml
(IQR: 12.5 to 30.0 ml) in IVUS-guided group (p < 0.001). The median volume of contrast/
creatinine clearance ratio was signiﬁcantly lower among patients treated with IVUS-guided PCI
(1.0 [IQR: 0.6 to 1.9] vs. 0.4 [IQR: 0.2 to 0.6], respectively; p < 0.001). In-hospital and 4-month
outcomes were not different between the angiography-guided and IVUS-guided groups.n EDITORIAL COMMENT
The Imperative of Reducing Contrast Dose in Percutaneous Coronary Intervention 1294
Kreton MavromatisPERIPHERAL VASCULAR Pressure-Wire-Guided Percutaneous Transluminal Pulmonary Angioplasty:
A Breakthrough in Catheter-Interventional Therapy for Chronic Thromboembolic
Pulmonary Hypertension1297Takumi Inami, Masaharu Kataoka, Nobuhiko Shimura, Haruhisa Ishiguro,
Ryoji Yanagisawa, Keiichi Fukuda, Hideaki Yoshino, Toru SatohPercutaneous transluminal pulmonary angioplasty (PTPA) has been demonstrated to be effective for
treatment of chronic thromboembolic pulmonary hypertension. However, a major and occasionally
fatal complication after PTPA has been reperfusion pulmonary edema. In this study, Inami et al.
demonstrated that the combined approach using pressure wire and the PEPSI (pulmonary edema
predictive scoring index) produced more efﬁcient clinical results and greatly reduced reperfusion
pulmonary edema and vessel complications. The pressure-wire-guided and PEPSI-guided
technique will make PTPA a standardized, safe, and promising therapeutic strategy for chronic
thromboembolic pulmonary hypertension.CONTINUED ON PAGE A-25
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NOVEMBER 2014 VOLUME 7, NUMBER 11Experience and Outcomes With Carotid Artery Stenting: An Analysis of the
CHOICE Study (Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes
Through the Collection of Clinical Evidence)1307Mehdi H. Shishehbor, Sridhar Venkatachalam, William A. Gray, Christopher Metzger,
Brajesh K. Lal, Lei Peng, Hend L. Omran, Eugene H. BlackstoneStudies on experience with protected carotid artery stenting (CAS) have focused only on operator and
institutional volumes. The authors sought to examine operator experience as measured by novel
time-related variables on 30-day death, stroke, and myocardial infarction using a multicenter
prospective (2006 to 2012) database (N ¼ 5,841). Speciﬁcally, time from ﬁrst CAS to each
subsequent CAS and time between each CAS were used. Additionally, embolic protection device dwell
time was used to assess technical performance. Using hierarchical multivariable models, operator
experience as measured by time from ﬁrst CAS and time between CAS were found to signiﬁcantly
affect technical performance and 30-day death, stroke, and myocardial infarction, respectively.n EDITORIAL COMMENT
Credentialing Operators for Carotid Artery Stenting:
Accepting the Occasional “Bad Apple” or Insisting on Airline Industry “Proﬁciency”1318Gary S. RoubinIMAGES IN
INTERVENTIONFeasibility of Anterior Mitral Leaﬂet Flail Repair With Transapical Beating-Heart
Neochord Implantation1320Andrea Colli, Erica Manzan, Fabio Zucchetta, Cristiano Sarais,
Demetrio Pittarello, Gino Gerosa
Acute Left Atrial Spontaneous Echocardiographic Contrast and Suspicious Thrombus
Formation Following Mitral Regurgitation Reduction With the MitraClip System1322Yohei Ohno, Guilherme F. Attizzani, Davide Capodanno, Fabio Dipasqua,
Marco Barbanti, Stefano Cannata, Sebastiano Immé, Margherita Ministeri, Anna Caggegi,
Anna M. Pistritto, Giuseppe Ronsivalle, Piera Capranzano, Sarah Mangiaﬁco,
Salvatore Scandura, Corrado Tamburino, Carmelo Grasso
Acute Artery Occlusion During Transcatheter Aortic Valve Replacement in a
Patient With an Anomalous Origin of the Circumﬂex Artery1324Juan Gabriel Acosta-Vélez, Bruno García del Blanco, Josep Guindo, Jose Montiel Serrano,
Hug Cuellar Calabria, Gerard Martí Aguasca, Teresa Gonzalez-Alujas, Ignasi Durán,
Pilar Tornos
n ONLINE FEATURE Transfemoral Balloon Mitral Valvuloplasty for
Severe Nonrheumatic Mitral Stenosise167Joseph T. Knapper, Gregory R. Hartlage, Stephen D. Clements
n ONLINE FEATURE Ruptured Neoatherosclerosis Presenting as a
Large Intrastent Neointimal Dissectione169Fernando Rivero, Javier Cuesta, Amparo Benedicto, Teresa Bastante, Fernando Alfonso
n ONLINE FEATURE Pacemaker Lead Entrapment Complicating
Transcatheter Closure of a Patent Foramen Ovalee171Henry C. Quevedo, Salman A. Arain, Nidal Abi RafehCONTINUED ON PAGE A-26
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NOVEMBER 2014 VOLUME 7, NUMBER 11n ONLINE FEATURE Kounis Syndrome Manifesting as Coronary Aneurysm and
Very Late Coronary Stent Thrombosise173Tomoya Hoshi, Akira Sato, Daiki Akiyama, Masayuki Kawabe, Daigo Hiraya,
Kazutaka Aonuma
n ONLINE FEATURE Transseptal Closure of Left Ventricular Pseudoaneurysm
Post-Transapical Transcatheter Aortic Valve Replacemente177Takashi Matsumoto, Kazuaki Okuyama, Wen Cheng, Raj R. Makkar, Saibal Kar
n ONLINE FEATURE Transradial Primary Percutaneous Intervention in a Rare Case
of Anomalous Origination of the Left Coronary Artery System From the
Right Aortic Sinuse179Savvas S. Constantinides, Vassilis I. Barberis, Lambros Mitselos, Christos P. Christou
n ONLINE FEATURE Index and Follow-Up Optical Coherence Tomography Imaging
Demonstrating Resolution of Post-Stent Intramural Hematoma Managed Conservativelye183Ashish Shah, Anirban Choudhury, Richard A. Anderson
n ONLINE FEATURE THESE ARTICLES DO NOT APPEAR IN THE PRINTED ISSUE.
THEY ARE AVAILABLE IN THE ONLINE VERSION OF THIS ISSUE.LETTERS TO
THE EDITORFirst-in-Man Transseptal Implantation of a “Surgical-Like” Mitral Valve Annuloplasty
Device for Functional Mitral Regurgitation1326Francesco Maisano, Giovanni La Canna, Azeem Latib, Paolo Denti, Maurizio Taramasso,
Karl Heinz Kuck, Antonio Colombo, Ottavio Alﬁeri, Andrea Guidotti,
David Messika-Zeitoun, Alec Vahanian
Experience With an Innovative New Food and Drug Administration Pathway for
First-in-Human Studies: Carotid Baroreceptor Ampliﬁcation for Resistant Hypertension1328Chandan M. Devireddy, Mark C. BatesEDITOR’S PAGE PCSK9: Is it Fluoride for Cardiology? 1331
Spencer B. King III
